Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170

Previous analyses of the phase 2 KEYNOTE-170 (NCT02576990) study demonstrated effective antitumor activity and acceptable safety of pembrolizumab 200 mg given every 3 weeks for up to 35 cycles (∼2 years) in patients with relapsed/refractory (R/R) primary mediastinal B-cell lymphoma (PMBCL) whose dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Zinzani, Pier Luigi, Thieblemont, Catherine, Melnichenko, Vladimir, Bouabdallah, Krimo, Walewski, Jan, Majlis, Alejandro, Fogliatto, Laura, Garcia-Sancho, A. Martin, Christian, Beth, Gulbas, Zafer, Özcan, Muhit, Perini, Guilherme Fleury, Ghesquieres, Herve, Shipp, Margaret A., Thompson, Seth, Chakraborty, Samhita, Marinello, Patricia, Armand, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651864/
https://www.ncbi.nlm.nih.gov/pubmed/37130017
http://dx.doi.org/10.1182/blood.2022019340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651864/
https://www.ncbi.nlm.nih.gov/pubmed/37130017
http://dx.doi.org/10.1182/blood.2022019340

Ejemplares similares